期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 50, 期 1, 页码 17-22出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2017.01.035
关键词
Community-acquired respiratory tract infection; Antibiotic susceptibility; Fourth-generation macrolide; Solithromycin
资金
- Cempra Pharmaceuticals
The activity of solithromycin, a fourth-generation macrolide and novel fluoroketolide, was evaluated by determining its minimum inhibitory concentration (MIC) (via Clinical and Laboratory Standards Institute broth microdilution) against 2797 contemporary clinical respiratory tract isolates collected from North America, Europe, Asia-Pacific and other regions of the world in 2012-13. Solithromycin was very active against Streptococcus pneumoniae and Streptococcus pyogenes, with MIC90 of 0.25 and 0.12 mu g/mL, respectively. Isolates with combined macrolide resistance genes ermB and mefE had a higher solithromycin MIC distribution, but the highest MIC recorded was 1 mu g/mL for one S. pneumoniae isolate fromJapan and one S. pyogenes isolate from China. Solithromycin was active against methicillin-susceptible Staphylococcus aureus (MIC90 0.12 mu g/mL) but not against methicillin-resistant S. aureus (MRSA) (MIC90 > 32 mu g/mL). However, MRSA strains most commonly observed with community-associated infections (i.e. SCCmec IV) were more susceptible than other MRSA SCCmec types. Gram-negative pathogens that cause community-acquired respiratory tract infections (Haemophilus influenzae and Moraxella catarrhalis) were inhibited by solithromycin isolated from worldwide locations (MIC90 2 and 0.25 mu g/mL, respectively). These data support the continued development of solithromycin for the treatment of community-acquired pneumonia globally. (C) 2017 Elsevier B. V. and International Society of Chemotherapy. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据